Asset Details
Do you wish to reserve the book?
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
Do you wish to request the book?
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
2010
Overview
Anti-inflammatory drugs are effective on relapses, but neuroprotective agents to prevent disability are still unavailable. Uric acid has neuroprotective effects in experimental models including encephalomyelitis and appears to be involved in multiple sclerosis. Oral administration of inosine, a precursor of uric acid, increases serum uric acid levels and is well tolerated. Our objective was to test the possibility that a combination therapy associating an anti-inflammatory drug (interferon β) and an endogenous neuroprotective molecule (uric acid) would be more effective than interferon β alone on the accumulation of disability. Patients with relapsing—remitting multiple sclerosis on interferon β for at least 6 months were randomized to interferon β + inosine or interferon β + placebo for 2 years. The dose of inosine was adjusted to maintain serum uric acid levels in the range of asymptomatic hyperuricaemia (≤10 mg/dl). The primary end points were percentage of patients with progression of disability and time to sustained progression (Kaplan—Meier analysis). The combination of interferon β and inosine was safe and well tolerated but did not provide any additional benefit on accumulation of disability compared with interferon β alone. We conclude that endogenous neuroprotective mechanisms recently identified in multiple sclerosis are complex and uric acid does not reflect the entire story.
Publisher
SAGE Publications
Subject
/ Anti-Inflammatory Agents - adverse effects
/ Anti-Inflammatory Agents - therapeutic use
/ Belgium
/ Female
/ Humans
/ Interferon-beta - adverse effects
/ Interferon-beta - therapeutic use
/ Male
/ Multiple Sclerosis, Relapsing-Remitting - blood
/ Multiple Sclerosis, Relapsing-Remitting - diagnosis
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Neuroprotective Agents - adverse effects
/ Neuroprotective Agents - metabolism
